Patients
NSCLC
DISEASE, NSCLC
The Combinatory ImmunoTherapy‐1 (ComIT‐1) trial is a multi‐center phase II trial conducted at three university hospitals in Norway. In this study, we included patients with advanced NSCLC (stages III–IV) previously treated with a platinum doublet. Eligible patients were > 18 years of age with an ECOG performance status score of 0 or 1, adequate organ and hematologic functions, measurable disease according to Response Evaluation Criteria in Solid Tumours version 1.1 (